Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
Desidustat in the Treatment of Anemia in CKD
- Conditions
- Chronic Kidney Disease Stage 3AnemiaChronic Kidney Disease Stage 4Chronic Kidney Disease Stage 5
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 588
- Registration Number
- NCT04012957
- Locations
- 🇮🇳
Sawai Man Singh (SMS) Medical College and Hospital, Jaipur, Rajasthan, India
🇮🇳Max Super Specialty Hospital, New Delhi, Delhi, India
🇮🇳Eternal Hospital, Jaipur, Rajasthan, India
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 46
- Registration Number
- NCT03992066
- Locations
- 🇺🇸
Research Site, Chattanooga, Tennessee, United States
Mechanisms of EPO-induced Hypertension
- Conditions
- Chronic Kidney DiseaseBlood PressureAnemia
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 27
- Registration Number
- NCT03810911
- Locations
- 🇺🇸
Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 320
- Registration Number
- NCT03776032
Maintenance Treatment of Renal Anemia in Dialysis Subjects
- Conditions
- Renal Insufficiency, ChronicAnemia
- Interventions
- Drug: Placebo of Molidustat (BAY85-3934)Drug: Placebo of Darbepoetin alfa
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 229
- Registration Number
- NCT03543657
- Locations
- 🇯🇵
Chibune Clinic, Osaka, Japan
🇯🇵Maruko Central Hospital, Ueda, Nagano, Japan
🇯🇵Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan
Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2018-05-31
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT03542916
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03446612
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
- Conditions
- Anemia; Hemodialysis Dependent Chronic Kidney Disease
- Interventions
- Drug: MT-6548-matching placebo
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 323
- Registration Number
- NCT03439137
- Locations
- 🇯🇵
Research site, Yamagata, Japan
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
- Conditions
- AnemiaRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 164
- Registration Number
- NCT03350347
- Locations
- 🇯🇵
Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan
🇯🇵Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan
🇯🇵Higashihiroshima Medical Center, Higashihiroshima, Hiroshima, Japan
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
- Conditions
- AnemiaRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 162
- Registration Number
- NCT03350321
- Locations
- 🇯🇵
Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan
🇯🇵St.Mary's Hospital, Kurume, Fukuoka, Japan
🇯🇵Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.